Revenue
No reported data
Tenaya Therapeutics, Inc. (TNYA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $68.6M | $86.7M | $98.0M | $94.5M | $54.4M | $31.1M |
| Operating expenses | $93.3M | $115.9M | $131.2M | $125.6M | $72.8M | $38.9M |
| Operating income | −$93.3M | −$115.9M | −$131.2M | −$125.6M | −$72.8M | −$38.9M |
| EBITDAderived | −$84.9M | −$107.5M | −$122.5M | −$119.2M | −$69.8M | −$36.4M |
| Net income | −$90.6M | −$111.1M | −$124.1M | −$123.7M | −$72.7M | −$38.4M |
| Basic EPSper diluted share | -$0.59 | -$1.31 | -$1.68 | -$2.76 | -$4.10 | -$39.50 |
| Diluted EPSper diluted share | -$0.59 | -$1.31 | -$1.68 | -$2.76 | -$4.10 | -$39.50 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Ali FarazChief Executive Officer | SellCommon Stock | 3.4K | $0.79 | $2.7K | 440.0K |
| May 18, 2026Form 4 | Tingley WhittemoreChief Medical Officer | SellCommon Stock | 3.1K | $0.79 | $2.5K | 215.5K |
| May 18, 2026Form 4 | Higa TomohiroSVP, Finance | SellCommon Stock | 1.5K | $0.79 | $1.2K | 118.3K |
| Feb 25, 2026Form 4 | TCG Opportunity III GP, LLC +7TenPercentOwner | SellCommon Stock · indirect | 1.86M | $0.56 | $1.04M | 0 |
| Feb 25, 2026Form 4 | TCG Opportunity III GP, LLC +7TenPercentOwner | SellCommon Stock · indirect | 1.65M | $0.56 | $923.6K | 0 |